- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2R-beta-gamma selectivity – - A Phase II program of ANV419 has been initiated in Melanoma and multiple combination trials, including in...

Basel, 29 July 2022 – Anaveon today announced that it will present new clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of...

Dr Phillips brings 30 years of healthcare leadership experience in commercial operations, business strategy, business development and drug development functions.

Anaveon, a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND application for ANV419-101, a Phase I/II mono treatment dose confirmation and combination dose-finding, global study, in patients with advanced cutaneous melanoma.

As of the March 11, 2022 data cut-off date, 16 patients in 7 dosing cohorts with different types of progressing cancer received ANV419 every 14 days. ANV419, administered intravenously over 15 minutes was exceptionally well tolerated with most patients experiencing a mild Grade 1 infusion-related reaction with chills and low-grade fever a few hours after dosing, which resolved with antipyretic treatment. No patients experienced a Grade 3 or worse drug related AE and no patients have withdrawn from study due to AEs. No dose limiting toxicities have been observed.